A Single-center, Randomized, Open-label, Two-period, Crossover Clinical Study to Evaluate the Bioavailability of Two Specifications of Oral Deuterium Deuremidevir for Hydrobromide Suspension in Chinese Healthy Adult Participants
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Deuremidevir hydrobromide (Primary)
- Indications COVID 2019 infections; Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 08 Apr 2025 Planned End Date changed from 15 Mar 2025 to 15 Jul 2025.
- 08 Apr 2025 Planned primary completion date changed from 15 Mar 2025 to 15 Jul 2025.
- 08 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Jun 2025.